FDA Hears Concerns About The Unregulated CBD Market

  • Forbes | by: Holly Lawrence |
  • 06/04/2019 12:00 AM
A Call for Regulatory Oversight

The FDA hearing’s first speaker, Peter Pitts, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner, set the theme. “The absence to date, of advanced regulatory thinking relative to CBD has resulted in a maelstrom of false claims and shoddy quality standards,” Pitts said.

He called out “aggressive and misleading marketing campaigns” for CBD products, and urged, “It’s time for the proponents of CBD, including many highly vocal patients, physicians, pharmacists, manufacturers and distributors, to become part of the solution.

“Quality must always trump corporate convenience,” Pitts said, expressing the need for production quality oversight.

He also described a lack of a dosing schedule for CBD products. “When people are told to use CBD by physicians, pharmacists, friends or internet experts, they are not given any peer-reviewed guidelines on how they should take it or in what amounts — something that should never happen,” Pitts said.

 
Sign Up for Our Email Newsletter

RECENT NEWS

World Health Organization: 70 COVID-19 Vaccines Under Development, With 3 In Human Trials

World Health Organization: 70 COVID-19 Vaccines Under Development, With 3 In Human Trials

Peter Pitts on Fox News Channel with Neil Cavuto "World Health Organization: 70 COVID-19 Vaccines Under Development, Wi...  Read more

FDA to Announce Tougher Standards for Coronavirus Vaccine

FDA to Announce Tougher Standards for Coronavirus Vaccine

Cheddar's Hena Doba is joined by Prof. Peter Pitts, Founder of the Center for Medicine in the Public Interest and Former ...  Read more

The Spreading Cancer of Counterfeit Drugs
  • CMPI
  • 10/01/2020 12:00 AM

The Spreading Cancer of Counterfeit Drugs

Just as the coronavirus mutates to survive and thrive, so to do the purveyors of counterfeit medicines -- with their high...  Read more

DRUGWONKS BLOG